The need for risk stratification in type 2 diabetes and chronic kidney disease: Proposed clinical value of KidneyIntelX

Autor: Marina Basina, Tracey L. McLaughlin, Joji Tokita, Aida Vega, Azadeh Zabetian, Allison Trucillo, Girish Nadkarni, Michael Donovan, Joseph Vassalotti, Steven G. Coca, David Lam

Publikováno v: Diabetic Nephropathy. 3:1-9

Chronic kidney disease (CKD) develops in > 40% of people living with diabetes and affects > 7 million people in the United States. Of the 15 million individuals with type 2 diabetes and CKD in the United States, > 90% are in the “early stages of CK

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cd95383ab7b0608c4015eb5d0ed16f34
https://doi.org/10.2478/dine-2022-0019

Chutes & Ladders—Gene editing biotech Metagenomi adds CSO, CFO.

Autor: Bayer, Max (AUTHOR), Masson, Gabrielle (AUTHOR)

Publikováno v: FierceBiotech. 11/10/2023, pN.PAG-N.PAG. 1p.

Epidemiology, methods of diagnosis, and clinical management of patients with arginase 1 deficiency (ARG1-D): A systematic review.

Autor: Bin Sawad A; Aeglea BioTherapeutics, Austin, TX, USA. Electronic address: abinsawad@aeglea.com., Jackimiec J; Aeglea BioTherapeutics, Austin, TX, USA., Bechter M; Aeglea BioTherapeutics, Austin, TX, USA., Trucillo A; Aeglea BioTherapeutics, Austin, TX, USA., Lindsley K; IQVIA, Inc, Durham, NC, USA., Bhagat A; IQVIA, Inc, Durham, NC, USA., Uyei J; IQVIA, Inc, Durham, NC, USA., Diaz GA; Division of Medical Genetics and Genomics in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Publikováno v: Molecular genetics and metabolism [Mol Genet Metab] 2022 Sep-Oct; Vol. 137 (1-2), pp. 153-163. Date of Electronic Publication: 2022 Aug 25.